Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT
Dan Sandberg(Uppsala University), Jens Sørensen(Uppsala University), Henrik Lindman(Uppsala University), Anders Wennborg(Affibody (Sweden)), Vladimir Tolmachev(Uppsala University), Jörgen Carlsson(Uppsala University Hospital), Irina Velikyan(Uppsala University), Helena Olofsson, Joachim Feldwisch(Uppsala University)
Cited by 60
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260